FATE THERAPEUTICS INC Interest Expense
FATE THERAPEUTICS INC (FATE) reported Interest Expense of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2022-02-28
- FATE THERAPEUTICS INC interest expense for the quarter ending 2019-12-31 was $538.00K, a 25.12% increase year-over-year.
- FATE THERAPEUTICS INC interest expense for the quarter ending 2019-09-30 was $400.00K, a 6.76% decline year-over-year.
- FATE THERAPEUTICS INC interest expense for the quarter ending 2019-06-30 was $409.00K, a 3.76% decline year-over-year.
- FATE THERAPEUTICS INC interest expense for the quarter ending 2019-03-31 was $405.00K, a 1.70% decline year-over-year.
- FATE THERAPEUTICS INC interest expense for fiscal 2021 was $0.00.
- FATE THERAPEUTICS INC interest expense for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- FATE THERAPEUTICS INC interest expense for fiscal 2019 was $1.75M, a 3.30% increase from fiscal 2018.
- FATE THERAPEUTICS INC interest expense for fiscal 2018 was $1.70M, a 33.75% increase from fiscal 2017.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month | Interest Expense 80 month | Interest Expense 83 month |
|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 | |||||
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 | |||||
| 2019-12-31 | $538.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $938.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.35M derived: sum of 3 quarters · filed 2022-02-28 | $1.75M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $400.00K 10-Q · filed 2020-11-05 | $809.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.21M 10-Q · filed 2020-11-05 | $1.64M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-06-30 | $409.00K 10-Q · filed 2020-08-05 | $814.00K 10-Q · filed 2020-08-05 | $1.24M derived: sum of 3 quarters · filed 2021-02-24 | $1.67M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-03-31 | $405.00K 10-Q · filed 2020-05-11 | $835.00K derived: sum of 2 quarters · filed 2021-02-24 | $1.26M derived: sum of 3 quarters · filed 2021-02-24 | $1.69M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2018-12-31 | $430.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $859.00K derived: sum of 2 quarters · filed 2021-02-24 | $1.28M derived: sum of 3 quarters · filed 2021-02-24 | $1.70M 10-K · filed 2021-02-24 | ||
| 2018-09-30 | $429.00K 10-Q · filed 2019-11-05 | $854.00K derived: sum of 2 quarters · filed 2019-11-05 | $1.27M 10-Q · filed 2019-11-05 | $1.68M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | $425.00K 10-Q · filed 2019-08-06 | $837.00K 10-Q · filed 2019-08-06 | $1.25M derived: sum of 3 quarters · filed 2020-03-02 | $1.63M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-03-31 | $412.00K 10-Q · filed 2019-05-07 | $824.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.20M derived: sum of 3 quarters · filed 2020-03-02 | $1.41M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2017-12-31 | $412.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $790.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.00M derived: sum of 3 quarters · filed 2020-03-02 | $1.27M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | $378.00K 10-Q · filed 2018-11-01 | $590.00K derived: sum of 2 quarters · filed 2018-11-01 | $856.00K 10-Q · filed 2018-11-01 | $1.19M derived: sum of 4 quarters · filed 2019-03-05 | ||
| 2017-06-30 | $212.00K 10-Q · filed 2018-08-06 | $478.00K 10-Q · filed 2018-08-06 | $807.00K derived: sum of 3 quarters · filed 2019-03-05 | $1.19M derived: sum of 4 quarters · filed 2019-03-05 | ||
| 2017-03-31 | $266.00K 10-Q · filed 2018-05-10 | $595.00K derived: sum of 2 quarters · filed 2019-03-05 | $980.00K derived: sum of 3 quarters · filed 2019-03-05 | $1.42M derived: sum of 4 quarters · filed 2019-03-05 | ||
| 2016-12-31 | $329.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $714.00K derived: sum of 2 quarters · filed 2019-03-05 | $1.15M derived: sum of 3 quarters · filed 2019-03-05 | $1.64M 10-K · filed 2019-03-05 | ||
| 2016-09-30 | $385.00K 10-Q · filed 2017-11-01 | $820.00K derived: sum of 2 quarters · filed 2017-11-01 | $1.31M 10-Q · filed 2017-11-01 | $1.84M derived: sum of 4 quarters · filed 2018-03-05 | ||
| 2016-06-30 | $435.00K 10-Q · filed 2017-08-14 | $923.00K 10-Q · filed 2017-08-14 | $1.46M derived: sum of 3 quarters · filed 2018-03-05 | $2.02M derived: sum of 4 quarters · filed 2018-03-05 | ||
| 2016-03-31 | $488.00K 10-Q · filed 2017-05-15 | $1.02M derived: sum of 2 quarters · filed 2018-03-05 | $1.59M derived: sum of 3 quarters · filed 2018-03-05 | $2.15M derived: sum of 4 quarters · filed 2018-03-05 | ||
| 2015-12-31 | $537.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $1.10M derived: sum of 2 quarters · filed 2018-03-05 | $1.66M derived: sum of 3 quarters · filed 2018-03-05 | $2.22M 10-K · filed 2018-03-05 | ||
| 2015-09-30 | $562.00K 10-Q · filed 2016-11-07 | $1.13M derived: sum of 2 quarters · filed 2016-11-07 | $1.68M 10-Q · filed 2016-11-07 | $1.97M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-06-30 | $563.00K 10-Q · filed 2016-08-08 | $1.12M 10-Q · filed 2016-08-08 | $1.41M derived: sum of 3 quarters · filed 2017-03-16 | $1.60M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-03-31 | $558.00K 10-Q · filed 2016-05-09 | $849.00K derived: sum of 2 quarters · filed 2017-03-16 | $1.04M derived: sum of 3 quarters · filed 2017-03-16 | $1.06M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2014-12-31 | $291.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $478.00K derived: sum of 2 quarters · filed 2017-03-16 | $506.00K derived: sum of 3 quarters · filed 2017-03-16 | $549.00K 10-K · filed 2017-03-16 | ||
| 2014-09-30 | $187.00K 10-Q · filed 2015-11-03 | $215.00K derived: sum of 2 quarters · filed 2015-11-03 | $258.00K 10-Q · filed 2015-11-03 | $636.00K derived: sum of 4 quarters · filed 2016-03-03 | ||
| 2014-06-30 | $28.00K 10-Q · filed 2015-08-05 | $71.00K 10-Q · filed 2015-08-05 | $449.00K derived: sum of 3 quarters · filed 2016-03-03 | $679.00K derived: sum of 4 quarters · filed 2016-03-03 | ||
| 2014-03-31 | $43.00K 10-Q · filed 2015-05-07 | $421.00K derived: sum of 2 quarters · filed 2016-03-03 | $651.00K derived: sum of 3 quarters · filed 2016-03-03 | $739.00K derived: sum of 4 quarters · filed 2016-03-03 | $2.68M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $608.00K derived: sum of 2 quarters · filed 2016-03-03 | $696.00K derived: sum of 3 quarters · filed 2016-03-03 | $796.00K 10-K · filed 2016-03-03 | $2.64M 10-K · filed 2014-03-17 | |
| 2013-09-30 | $230.00K 10-Q · filed 2014-11-12 | $318.00K derived: sum of 2 quarters · filed 2014-11-12 | $418.00K 10-Q · filed 2014-11-12 | |||
| 2013-06-30 | $88.00K 10-Q · filed 2014-08-12 | $188.00K 10-Q · filed 2014-08-12 | ||||
| 2013-03-31 | $100.00K 10-Q · filed 2014-05-13 | |||||
| 2012-12-31 | $487.00K 10-K · filed 2015-03-12 | |||||
| 2011-12-31 | $127.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |